MedTrace Logo

BLAZE-Limiting Approach in NMOSD

NCT06888622 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2025-03-21

No results posted yet for this study

Summary

This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651). Between October 2023 (when eculizumab was approved for NMOSD in China) and February 2025, 26 consecutive patients with AQP4-IgG-positive NMOSD received eculizumab, and 9 of them were included in this study.

Conditions

  • Neuromyelitis Optica Spectrum Disorders (NMOSD)

Interventions

DRUG

Eculizumab administration

Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Chao Quan, Doctor · Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2025-03-01
Completion
2025-03-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06888622 on ClinicalTrials.gov